REVENUES

6 Months Ended

Jun. 30, 2021

REVENUES

REVENUES

NOTE 4 – REVENUES

The following table summarizes the Company’s disaggregation of revenues:

	Three Months Ended June 30,				Six Months Ended June 30,
(U.S. dollars in thousands)	2021		2020		2021		2020
Pfizer	$	2,237	$	663	$	6,748	$	2,679
Brazil	$	988	$	2,985	$	988	$	6,000
Chiesi	$	18	$	—	$	18	$	—
Total revenues from selling goods	$	3,243	$	3,648	$	7,754	$	8,679
Revenues from license and R&D services	$	3,184	$	7,319	$	9,993	$	23,934

During the six months ended June 30, 2020, and following the CRL received from the FDA, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in a reduction to accumulated revenues recognized in respect of this performance obligation in the amount of $4.1 million.

During the six months ended June 30, 2021 and 2020, the Company recognized revenues of approximately $0.9 million and $1.2 million, respectively, and during each of the three months ended June 30, 2021 and 2020, the Company recognized revenues of approximately $0.5 million all related to a $10.0 million future milestone payment, which was accounted for as a variable consideration. The $10.0 million payment was received in June 2021.